LASAACI 2025 Fall Symposium

Los Angeles, CA US
September 20, 2025

The Los Angeles Society of Allergy, Asthma and Clinical Immunology (LASAACI) is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology (ACAAI) and the LASAACI.  
The 2025 program is a four-hour event with Faculty who are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Los Angeles Society of Allergy, Asthma & Clinical Immunology (LASAACI). The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours.

No commerical support was received for this activity.

Target Audience

Practicing allergists
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity, attendees should be able to:

CRSwNP
•    Become familiar with state-of-the-art diagnosis and treatment of CRSwNP
•    Integrate treatment algorithm for CRSwNP.
•    Identify deficits in current knowledge regarding biologics for CRSwNP.
•    Review mechanisms of action of current biologics and possible modulatory effects on immunologic/inflammatory persistence
•    Review evolving therapeutic strategies, including inhaled antifungal therapies and biologic medications

Asthma
•    Review inflammatory pathways and long-term consequences of inflammation in asthma
•    Review evolving therapeutic strategies including inhale antifungal therapies and biologic medications
•    Review mechanisms of action of current biologics and possible modulatory effects on immunologic/inflammatory persistence

Atopic Dermatitis
•    Describe non-pharmacologic approaches to treating atopic dermatitis, including creating an eczema action plan.
•    Outline potential benefits of a multi-pronged therapeutic approach to AD
•    Identify pitfalls, limitations, and knowledge gaps in AD
•    Describe the existing systemic therapies that are commonly used for treating AD
•    Outline key pathophysiologic pathways being targeted for emerging treatments
•    Identify some key studies on emerging therapies for AD

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
09/20/2025
Course expires: 
12/31/2025
Event starts: 
09/20/2025 - 8:00am CDT
Event ends: 
09/20/2025 - 3:30pm CDT
Add to calendar: 
Rating: 
0

LASAACI 2025 Fall Symposium
Saturday, September 20, 2025

Skirball Cultural Center, Los Angeles CA

All Education Sessions to be held in Herscher Hall C
Exhibits and Coffee Breaks to be held in Herscher Hall B

7:20AM-8:20AM        Registration, Exhibits & Coffee Break

GENERAL SESSION
8:20AM-8:30AM        WELCOME AND INTRODUCTION, Sheila Bonilla, MD, LASAACI President/Program Director
Session Moderator: Sheila Bonilla, MD

8:30AM-9:30AM    Advancements in the Management of Chronic Rhinosinusitis with Nasal Polyps, Nadia Chan, MD
Q & A

9:30AM-10:30AM    Pediatric Asthma: GINA 2025 and NAEPP 2020 Guideline Updates, Theresa Guilbert, MD, MS
Q & A

10:30AM-11:30AM    Buffet Brunch, Exhibits, Posters

11:30AM-12:30PM    The Skin Microbiome in Atopic Dermatitis, Tissa R. Hata, MD
Q & A

12:30PM-1:30PM    Early Life Exposures Guide Immune System Development, Petter Brodin MD, PhD
in Human Newborns
Q & A

1:30PM    Adjourn
 

Skirball Cultural Center
2701 N. Sepulveda Blvd
Los Angeles, CA 90049
United States

All relevant financial relationships with ineligible companies have been mitigated.

Sheila Bonilla, MD – Planner, Moderator
Advisor: KalVista

Sonal Patel, MD – Planner
Speaker: Sanofi, Regeneron

Petter Brodin, MD, PhD – Speaker
Independent contractor: Pfizer
Executive board member: Kancera 
Advisor: Pixelgen Technologies AB, Sention Health AB, Helaina Inc., Scailyte AG, Oxford Immune Algorithmics

Theresa Guilbert, MD, MS – Speaker
Advisor: AstraZeneca, OM Pharma, Regeneron/Amgen, Sanofi
Researcher: AstraZeneca, GSK, OM Pharma, Regeneron/Amgen, Sanofi
Royalties: UpToDate

Tissa Hata, MD – Speaker
Researcher: Bristol Meyers Squibb, Pfizer, Unilever

The following have no relevant financial relationships with ineligible companies to disclose:

Karol Anderson – Planner
Edward Hu, MD – Planner
Marilyn Li, MD – Planner
Rita Kachru, MD – Planner
Shefali Samant, MD – Planner
Caroline Spagnola, MD – Planner
Andrew K. Wong, MD – Planner
Nadia Chan, MD – Speaker

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.